Abstract
Whereas most pain due to cancer can be relieved with relatively simple methods using oral analgesics, as suggested by WHO guidelines, some patients may have difficult pain situations that require more complex approaches. It is estimated that 10–20 % of cancer patients suffer from pain that is not easily relieved. There are a number of factors that may reduce the efficacy of opioids in the management of cancer pain. Neuropathic pain (NP) and breakthrough pain (BP), especially of the incident subtype, have been identified as challenges for clinicians. In several prognostic studies, these two mechanisms were associated with limited positive outcomes compared with other syndromes. Opioid-induced hyperalgesia has recently been described as representing a challenge for physicians in the clinical setting. The global response to opioids, including the development of adverse effects, typically varies by individual and is likely genetically determined. Moreover, clinical evidence suggests that different opioids may produce different effect profiles, and so it is more appropriate to consider the response to each individual opioid rather than general opioid response. This paper will review both pharmacological and procedural mechanisms and treatments of these difficult pain syndromes.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of particular importance
Paice JA, Ferrell B. The management of cancer pain. CA Cancer J Clin. 2011;61:157–82.
Hanks GW, de Conno F, Cherny N, et al. Expert working group of the research network of the European association for palliative care. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer. 2001;84:587–931.
Fainsinger RL, Nekolaichuk C, Lawlor P, et al. An international muticentre validation study of a pain classification system for cancer patients. Eur J Cancer. 2010;46:2896–904.
Knudsen AK, Brunelli C, Kaasa S, et al. Which variables are associated with pain intensity and treatment response in advanced cancer patients? Implications for a future classification system for cancer pain. Eur J Pain. 2011;15:320–7.
Mercadante S, Portenoy RK. Opioid poorly-responsive cancer pain. Part 1: clinical considerations. J Pain Symptom Manage. 2001;21:144–50.
Stute P, Soukup J, Menzel M, Sabatowski R, Grond S. Analysis and treatment of different types of neuropathic cancer pain. J Pain Symptom Manage. 2003;26:1123–31.
Davis MP. What is new in neuropathic pain? Supp Care Cancer. 2007;15:363–72.
• Jensen TS, Gottrup H, Sindrup SH, Bach FW. The clinical picture of neuropathic pain. Eur J Pharmacol. 2001;429:1–11. Authoritative review of clinical assessment of neuropathic pain.
•• Bennett MI, Smith BH, Torrance N, Lee AJ. Can pain can be more or less neuropathic? Comparison of symptom assessment tools with ratings of certainty by clinicians. Pain. 2006;122:289–94. This paper produced new insights in the concept of neuropathic pain.
Fainsinger R, Nekolaichuk C, Lawlor P, Neumann C, Hanson J, Viganò A. A multicenter study of the revised Edmonton staging system for classifying cancer pain in advanced cancer patients. J PainSymptomManage. 2005;29:224–37.
• Mercadante S, Gebbia V, David F, et al. Tools for identifying cancer pain of predominantly neuropathic origin and opioid responsiveness in cancer patients. J Pain. 2009;10:594–600. This paper analyzed the concept of neuropathic pain and the relative opioid response in the clinical setting.
Bennett MI. Effectiveness of antiepileptic or antidepressant drugs when added to opioids for cancer pain: a systematic review. Palliat Med. 2011;25:553–9.
Bell RF, Eccleston C, Kalso E. Ketamine as adjuvant to opioids for cancer pain. A qualitative systematic review. J Pain Symptom Manage. 2003;26:867–75.
Hardy J, Quinn S, Fazekas B, et al. Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. J Clin Oncol. 2012;30:3611–7.
Mercadante S. Ketamine: to be or not to be. Ann Palliat Med. 2013;2:37–9.
Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. A Comprehensive review of opioid-induced hyperalgesia. Pain Phys. 2011;14:145–61.
Chang G, Chen L, Mao J. Opioid tolerance and hyperalgesia. Med Clin North Am. 2007;91:199–211.
Silverman S. Opioid induced hyperalgesia: clinical implications for the pain practitioner. Pain Phys. 2009;12:679–84.
• Mercadante S, Bruera E. Opioid switching: a systematic and critical review. Cancer Treat Rev. 2006;32:304–15. An outstanding review of opioid switching in cancer pain.
Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G. The management of cancer-related breakthrough pain: recommendations of a task group of the science committee of the association for palliative medicine of Great Britain and Ireland. Eur J Pain. 2009;13:331–8.
Caraceni A, Martini C, Zecca E, et al. Working group of an IASP task force on cancer pain. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med. 2004;18:177–83.
Nomiya T, Teruyama K, Wada H, Nemoto K. Time course of pain relief in patients treated with radiotherapy for cancer pain: a prospective study. Clin J Pain. 2010;26:38–42.
Mercadante S, Villari P, Ferrera P, Casuccio A. Optimization of opioid therapy for preventing incident pain associated with bone metastases. J Pain Symptom Manage. 2004;28:505–10.
• Mercadante S. Pharmacotherapy for breakthrough cancer pain. Drugs. 2012;72:181–90. An updated reviews of drugs used for breakthrough pain.
Mercadante S. Breakthrough pain: on the road again. Eur J Pain. 2009;13:329–30.
Mercadante S. Neuraxial techniques for cancer pain: an opinion about unresolved therapeutic dilemmas. Reg Anesth Pain Med. 1999;24:74–83.
Mercadante S, Intravaia G, Villari P, et al. Intrathecal treatment in cancer patients unresponsive to multiple trials of systemic opioids. Clin J Pain. 2007;23:793–8.
Mercadante S. Malignant bone pain: physiopathology, assessment and treatment. Pain. 1997;69:1–18.
Mercadante S, Fulfaro F. Management of painful bone metastases. Curr Opin Oncol. 2007;19:308–14.
Brogan S, Junkins S. Interventional therapies for the management of cancer pain. J Support Oncol. 2010;8:52–9.
Biermann JS, Holt GE, Lewis VO, Schwartz HS, Yaszemski MJ. Metastatic bone disease: diagnosis, evaluation and treatment. J Bone Joint Surg Am. 2009;91:1518–30.
Compliance with Ethics Guidelines
Conflict of Interest
Dr. Sebastiano Mercadante declares no potential conflicts of interest relevant to this article.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is part of the Topical Collection on Cancer Pain
Rights and permissions
About this article
Cite this article
Mercadante, S. Managing Difficult Pain Conditions in the Cancer Patient. Curr Pain Headache Rep 18, 395 (2014). https://doi.org/10.1007/s11916-013-0395-y
Published:
DOI: https://doi.org/10.1007/s11916-013-0395-y